The SLC4A3 antibody targets the solute carrier family 4 member 3 (SLC4A3), a gene encoding anion exchanger 3 (AE3), a membrane protein crucial for bicarbonate (HCO₃⁻) transport and intracellular pH regulation. AE3 exists in two splice variants: the cardiac-type AEc3. predominantly expressed in the heart, retina, and brain, and the brain-type AEb3. found in neurons and epithelial cells. SLC4A3 facilitates electroneutral Cl⁻/HCO₃⁻ exchange, maintaining acid-base homeostasis in tissues with high metabolic activity. Dysregulation of AE3 is linked to pathologies such as cardiac hypertrophy, epilepsy, and retinal disorders. In cancer, SLC4A3 exhibits dual roles—acting as a tumor suppressor in some contexts by modulating apoptosis or promoting metastasis through microenvironmental acidification. The SLC4A3 antibody is widely used in research to study protein expression, localization (e.g., plasma membrane vs. intracellular organelles), and functional interactions via techniques like Western blot, immunohistochemistry, and immunofluorescence. It also aids in exploring AE3's involvement in ion transport mechanisms and disease pathways. Validation typically includes testing in knockout models or tissues with known expression profiles to ensure specificity. Ongoing studies focus on its therapeutic potential in pH-dependent disorders and cancer.